Compare National Beverage Corp. (FIZZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novavax Inc — how do they compare? National Beverage Corp. trades at $30.63 (market cap $2.89B), while Novavax Inc trades at $7.91 (market cap $1.31B). The key difference: National Beverage Corp. is far larger — about 2.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | NVAX | |
|---|---|---|
Market Cap | $2.89B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $11.19 |
52-Week Low | $30.53 | $6.22 |
Enterprise Value | $2.60B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.45, down 1.9% on the day, with a bearish technical signal and recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margin improved to 15.56% in 2025. The company announced a special dividend of $3.25 per share, payable in July 2026, but faces declining LaCroix volumes and muted growth prospects.
The outlook is cautious due to stalled growth and bearish analyst sentiment, with 50% of coverage rating Sell. Risks include competitive pressures and weak volume trends, though the dividend provides some shareholder return. Upside appears limited without a clear catalyst for revenue acceleration.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
